【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 11
1.2 List of Figures 13
2 Introduction 15
2.1 What Is This Report About? 15
3 Definitions of Markets/Categories Covered 16
3.1 Cardiovascular Devices 16
3.1.1 Electrophysiology 16
3.1.2 Peripheral Vascular Devices 16
3.2 Nephrology and Urology Devices 16
3.2.1 Incontinence Devices 16
3.3 Drug Delivery Devices 16
3.3.1 Central Venous Catheters 16
4 Company Snapshot 17
4.1 Key Facts 17
4.2 Company Overview 17
4.3 Financial Performance 17
4.4 SWOT Snapshot 17
5 Business Description 18
5.1 Business Overview 18
5.2 Oncology Product Line 18
5.2.1 Overview 18
5.2.2 Financials 18
5.3 Other Products Product Line 18
5.3.1 Overview 18
5.3.2 Financials 18
5.4 Surgical Specialties Product Line 18
5.4.1 Overview 18
5.4.2 Financials 19
5.5 Urology Product Line 19
5.5.1 Overview 19
5.5.2 Financials 19
5.6 Vascular Product Line 19
5.6.1 Overview 19
5.6.2 Financials 20
5.6.3 Market View 20
5.7 Major Products and Services 20
5.7.1 Overview 20
6 History 22
7 SWOT Analysis 25
7.1 Overview 25
7.2 C. R. Bard, Inc. Strengths 25
7.2.1 Diversified Business Operations 25
7.2.2 Sturdy Research and Development Activities 26
7.2.3 Constant Growth in Revenues 26
7.3 C. R. Bard, Inc. Weaknesses 26
7.3.1 Legal Proceedings and Product Recalls 26
7.3.2 Dependence on the US Market 26
7.4 C. R. Bard, Inc. Opportunities 27
7.4.1 Expansion through Acquisitions 27
7.4.2 Pipeline Clinical Trials 27
7.4.3 Global Nephrology and Urology Devices Market 27
7.5 C. R. Bard, Inc. Threats 28
7.5.1 Stringent Government Regulations 28
7.5.2 Shift in Technology 28
7.5.3 Healthcare Reform Bill 28
8 Competitors 29
9 Competitive Landscape 30
9.1 Cardiovascular Devices (Peripheral Vascular Devices), Global, Market Share (%), 2011 30
9.2 C. R. Bard, Inc., Cardiovascular Devices (Peripheral Vascular Devices), by Region, Market Share (2011) 32
9.3 C. R. Bard, Inc., Cardiovascular Devices (Peripheral Vascular Devices), by Country, Market Share (2011) 33
9.4 Cardiovascular Devices (Electrophysiology), Global, Market Share (%), 2011 35
9.5 C. R. Bard, Inc., Cardiovascular Devices (Electrophysiology), by Region, Market Share (2011) 37
9.6 C. R. Bard, Inc., Cardiovascular Devices (Electrophysiology), by Country, Market Share (2011) 38
9.7 Drug Delivery Devices (Central Venous Catheters), Global, Market Share (%), 2011 40
9.8 C. R. Bard, Inc., Drug Delivery Devices (Central Venous Catheters), by Region, Market Share (2011) 42
9.9 C. R. Bard, Inc., Drug Delivery Devices (Central Venous Catheters), by Country, Market Share (2011) 43
9.10 Nephrology and Urology Devices (Incontinence Devices), Global, Market Share (%), 2011 45
9.11 C. R. Bard, Inc., Nephrology and Urology Devices (Incontinence Devices), by Region, Market Share (2011) 47
9.12 C. R. Bard, Inc., Nephrology and Urology Devices (Incontinence Devices), by Country, Market Share (2011) 48
10 C. R. Bard, Inc. Medical Equipment Market Share Analysis by Category 50
10.1 C. R. Bard, Inc., Global, Category Revenue Share (2011) 50
10.2 C. R. Bard, Inc., Asia-Pacific, Category Revenue Share (2011) 52
10.2.1 C. R. Bard, Inc., Australia, Category Revenue Share (2011) 54
10.2.2 C. R. Bard, Inc., China, Category Revenue Share (2011) 56
10.2.3 C. R. Bard, Inc., India, Category Revenue Share (2011) 58
10.2.4 C. R. Bard, Inc., Japan, Category Revenue Share (2011) 60
10.2.5 C. R. Bard, Inc., Other Asia-Pacific, Category Revenue Share (2011) 62
10.3 C. R. Bard, Inc., Europe, Category Revenue Share (2011) 64
10.3.1 C. R. Bard, Inc., France, Category Revenue Share (2011) 66
10.3.2 C. R. Bard, Inc., Germany, Category Revenue Share (2011) 68
10.3.3 C. R. Bard, Inc., Italy, Category Revenue Share (2011) 70
10.3.4 C. R. Bard, Inc., Spain, Category Revenue Share (2011) 72
10.3.5 C. R. Bard, Inc., United Kingdom, Category Revenue Share (2011) 74
10.3.6 C. R. Bard, Inc., Other Europe, Category Revenue Share (2011) 76
10.4 C. R. Bard, Inc., Middle East and Africa, Category Revenue Share (2011) 78
10.5 C. R. Bard, Inc., North America, Category Revenue Share (2011) 80
10.5.1 C. R. Bard, Inc., Canada, Category Revenue Share (2011) 82
10.5.2 C. R. Bard, Inc., United States, Category Revenue Share (2011) 84
10.6 C. R. Bard, Inc., South and Central America, Category Revenue Share (2011) 86
10.6.1 C. R. Bard, Inc., Brazil, Category Revenue Share (2011) 88
10.6.2 C. R. Bard, Inc., Other South and Central America, Category Revenue Share (2011) 90
11 Key Employees 92
12 Key Employee Biographies 93
13 Company Statement 94
14 Locations And Subsidiaries 97
14.1 Head Office 97
14.2 Other Locations & Subsidiaries 97
15 Financial Deals Landscape 101
15.1 C. R. Bard, Inc., Deals Volume Summary, 2007 to 2012 101
16 C. R. Bard, Inc. Detailed Deal Summary 103
16.1 Asset Purchase 103
16.1.1 PacerView Technologies Sells PacerView Technology To Bard Access Systems 103
16.1.2 Spire Completes Sale Of Hemodialysis Catheter Business To Bard Access Systems For $12.5 Million 104
16.1.3 Davol Acquires XenMatrix From Brennen Medical For $17 Million 106
16.1.4 Edwards Lifesciences Sells LifeStent Product Line Assets To C. R. Bard For $140 Million 107
16.1.5 C. R. Bard Acquires Assets From Inrad 109
16.1.6 C. R. Bard Acquires EasyTac From Agency for Medical Innovations 110
16.2 Venture Financing 111
16.2.1 NeoMend Secures $10 Million In Financing 111
16.2.2 Lutonix Secures $10 Million In Series C Financing 112
16.2.3 Neomend Raises $33 Million In Venture Financing 113
16.2.4 NeoMend Secures $30 Million In Series D Financing Round 115
16.2.5 Medivance Secures $8 Million In New Venture Financing Round 117
16.2.6 Lutonix Secures $20 Million In Series B Financing 118
16.2.7 NeoMend Secures An Additional $15 Million In Series C Financing 119
16.2.8 FlowCardia Raises $30 Million In Series C Financing 120
16.2.9 NeoMend Secures $10.02 Million In Series C Funding 122
16.2.10 Lutonix Secures $5 Million In Series A Financing 123
16.3 Private Equity 124
16.3.1 Protostar Equity Partners Acquires Minority Stake In SenoRx 124
16.4 Partnerships 125
16.4.1 Covalon Technologies Expands Agreement With C. R. Bard 125
16.4.2 Covalon Technologies Signs Licensing Agreement With C. R. Bard 126
16.4.3 ClearStream Technologies Enters Into Licensing Agreement With C. R. Bard 127
16.4.4 C. R. Bard Signs Licensing Agreement With Genzyme 128
16.4.5 TyRx Pharma Enters Into Licensing Agreement With C. R. Bard 129
16.4.6 RTI Biologics Expands Distribution Agreement With Davol For Tutoplast Sterilized Dermal Allografts 130
16.4.7 Terason Ultrasound Enters Into Technology Integration Agreement With SenoRx 131
16.4.8 Medegen Signs An Agreement With C. R. Bard 132
16.4.9 IDev Technologies Enters Into A Distribution Agreement With YMed 133
16.4.10 Maelor Enters Into Distribution Agreement With Bard Limited 134
16.4.11 Cordis Enters Into Distribution Agreement With ClearStream Technologies 135
16.5 Equity Offering 136
16.5.1 ClearStream Technologies Completes Private Placement For $2 Million 136
16.5.2 ClearStream Technologies Completes Private Placement Of $5.6 Million 137
16.5.3 ClearStream Technologies Completes Private Placement Of $0.92 Million 138
16.5.4 ClearStream Technologies Completes Private Placement Of $1.8 Million 139
16.5.5 SenoRx Completes IPO Of $50.6 Million 140
16.5.6 C. R. Bard Completes Public Offering Of Senior Unsecured Notes Due 2016 For $250 Million 141
16.5.7 C. R. Bard Completes Public Offering Of Senior Unsecured Notes Due 2021 For $500 Million 143
16.6 Acquisition 145
16.6.1 C. R. Bard Acquires Lutonix 145
16.6.2 C. R. Bard Completes Acquisition Of Medivance For $250 Million 146
16.6.3 C. R. Bard Completes Acquisition Of Clearstream Technologies For $69 Million 148
16.6.4 C. R. Bard Completes Acquisition Of SenoRx For $213 Million 150
16.6.5 C.R. Bard Acquires Remaining 15% Stake In Bard Sendirian For $26 Million 152
16.6.6 C. R. Bard Completes Acquisition Of FlowCardia For $80.1 Million 153
16.6.7 C. R. Bard Acquires Y-Med For $35.3 Million 155
16.6.8 C. R. Bard Acquires Specialized Health Products International For $68 Million 156
17 Recent Developments 158
17.1 Strategy And Business Planning 158
17.1.1 May 10, 2012: C R Bard Creates 200 New Jobs Through Puerto Rican Expansion 158
17.1.2 Dec 13, 2010: Bard To Improve Overall Cost Structure And Enhance Operational Effectiveness 158
17.2 Financial Announcements 159
17.2.1 Jan 31, 2013: Bard Reports Revenue Of $3 Billion In 2012 159
17.2.2 Oct 23, 2012: Bard Reports Revenue Of $722.9m In Q3 2012 160
17.2.3 Jul 25, 2012: Bard Reports Revenue Of $742.6m In Q2 2012 160
17.2.4 Apr 24, 2012: Bard Reports Revenue Of $730m In Q1 2012 160
17.2.5 Jan 31, 2012: Bard Reports Revenue Of $2.9 Billion In 2011 161
17.2.6 Oct 25, 2011: Bard Reports Revenues Of $719.2m In Q3 2011 161
17.2.7 Jul 21, 2011: Bard Reports Net Sales Of $725m In Q2 2011 162
17.2.8 Apr 21, 2011: Bard Reports Net Sales Of $700.3m In Q1 2011 162
17.2.9 Jan 31, 2011: Bard Reports Net Sales of $2.72 Billion In 2010 163
17.2.10 Oct 21, 2010: Bard Reports Net Income Of $127.50 Million In Q3 2010 163
17.2.11 Jul 22, 2010: Bard Reports Net Income Of $124.7 Million For Q2 2010 164
17.2.12 Apr 22, 2010: Bard Reports Net Income Of $121.2 Million In Q1 2010 164
17.2.13 Jan 28, 2010: Bard Reports Net Income Of $461.4 Million In 2009 165
17.2.14 Oct 21, 2009: C.R. Bard Reports Net Income Of $130 Million In Q3 2009 165
17.2.15 Jul 22, 2009: Bard Posts Net Income Of $112.2 Million For Q2 2009 166
17.2.16 Jul 22, 2009: CR Bard Q2 Net Income Up 44% 166
17.2.17 Apr 22, 2009: Bard Posts Net Income Of $112.5 Million For Q1 2009 167
17.2.18 Jan 29, 2009: Bard Reports 2008 Results 167
17.2.19 Dec 10, 2008: Bard Reports Quarterly Dividend 168
17.2.20 Oct 22, 2008: Bard Reports 3Q 2008 Results 168
17.2.21 Oct 15, 2008: Bard To Declare 3Q 2008 Results 168
17.2.22 Oct 08, 2008: Bard Reports Quarterly Dividend 168
17.2.23 Jul 23, 2008: Bard Declares 2Q 2008 Results 169
17.2.24 Jun 11, 2008: Bard Reports Quarterly Dividend 169
17.2.25 Apr 23, 2008: Bard Reports Q1 2008 Results 170
17.2.26 Apr 16, 2008: Bard Reports Quarterly Dividend 170
17.2.27 Apr 15, 2008: Bard To Declare Q1 2008 Results 170
17.2.28 Jan 31, 2008: Bard Reports Q4 2007 Results 171
17.2.29 Dec 12, 2007: Bard Declares Quarterly Dividend 171
17.2.30 Oct 23, 2007: Bard Reports Q3 2007 Results 172
17.2.31 Oct 10, 2007: Bard Declares Quarterly Dividend 173
17.2.32 Oct 10, 2007: Bard Announces Share Repurchase Program 173
17.2.33 Jul 24, 2007: Bard Reports Q2 2007 Results 173
17.2.34 Jun 13, 2007: Bard Declares Quarterly Dividend 174
17.2.35 Apr 24, 2007: Bard Reports Q1 2007 Results 174
17.2.36 Apr 18, 2007: Bard Declares Quarterly Dividend 175
17.2.37 Jan 25, 2007: Bard Reports Q4 2006 Results 175
17.3 Corporate Communications 177
17.3.1 Nov 26, 2012: C.R. Bard To Lay Off 54 Workers From Queensbury Plant 177
17.3.2 Apr 30, 2012: C R Bard Appoints Christopher S Holland As CFO 177
17.3.3 Dec 02, 2011: C.R. Bard Plans To Cut 50 Jobs From Queensbury Plant 177
17.3.4 Aug 01, 2011: Bard Announces Retirement Of Todd Schermerhorn As Senior Vice President And CFO 178
17.3.5 Feb 10, 2011: C.R. Bard To Cut 200 Jobs From Queensbury Plant 178
17.3.6 Feb 10, 2011: Bard Appoints Todd Garner As Vice President, Investor Relations 178
17.3.7 Feb 10, 2011: C. R. Bard To Reduce Workforce By 20% 179
17.3.8 Apr 13, 2009: Bard Announces Promotion Of Jim C. Beasley To Group Vice President 179
17.3.9 Jun 25, 2008: Bard Announces Executive Promotion 179
17.4 Legal and Regulatory 180
17.4.1 Jan 15, 2013: C R Bard Wins Round As Supreme Court Rejects Gore Patent Appeal 180
17.4.2 Aug 06, 2012: Jury Returns $5.5m Verdict Against C.R. Bard In Transvaginal Mesh Lawsuit 180
17.4.3 Jul 06, 2011: C.R. Bard Extends Settlement In Kugel Mesh Litigation 181
17.4.4 Aug 18, 2010: Atrium Responds To Bard Suit 181
17.4.5 Mar 11, 2010: FDA Issues Warning On Counterfeit Surgical Mesh 182
17.4.6 Sep 29, 2009: Bard Gets Favorable Ruling In Class Action Lawsuit 183
17.4.7 Jul 30, 2008: US District Court Rules In Favor Of Bard On Patent Violation Suit Against Gore 183
17.5 Product News 183
17.5.1 Nov 02, 2012: C. R. Bard Receives FDA 510(k) Approval For Ajust Helical Adjustable Single Incision Sling 183
17.5.2 Jul 27, 2012: Bard Announces Enrollment Completion Of Lutonix Drug-Coated Balloon Clinical Trial And Initiation Of Large Continuation Registry Study 184
17.5.3 Jul 25, 2012: Bard Announces Enrollment Completion Of Lutonix Drug-Coated Balloon Clinical Trial And Initiation Of Large Continuation Registry Study 184
17.5.4 Jun 15, 2010: C.R. Bard Announces Publication Of RESILIENT Trial Results Of Bard LIFESTENT Vascular Stent 185
17.5.5 Feb 16, 2010: C.R. Bard To Complete Clinical Trial For Bard Ventrio Hernia Patch In First Half Of 2011 186
17.5.6 Sep 08, 2009: Bard To Complete Phase I Trial For RESTORe Suturing System In Second Half Of 2010 186
17.5.7 Sep 02, 2009: Bard To Complete The Phase III Trial For BARD HD MESH Ablation System In First Half Of 2011 186
17.5.8 Jul 22, 2009: C.R. Bard Plans To Introduce Ultraverse.018 Balloon 187
17.5.9 Jul 22, 2009: C.R. Bard Plans To Launch .014 Ultra Low Profile Balloon 187
17.5.10 Jul 22, 2009: C.R. Bard Plans To Launch LifeStent Product Enhancements 187
17.5.11 Feb 17, 2009: C. R. Bard Receives US FDA Approval To Market LifeStent FlexStar Vascular Stent Systems 187
17.5.12 Dec 08, 2008: Bard Receives FDA Approval For The E-Luminexx Vascular Stent 188
17.5.13 Aug 20, 2008: C. R. Bard Inc. Published Clinical Study Results Of Agento I.C. Silver-Coated Endotracheal Tube 188
17.5.14 Nov 08, 2007: Bard Receives Clearance To Market Agento IC Silver-Coated Endotracheal Tube 188
17.6 Product Approvals 189
17.6.1 Nov 02, 2012: C. R. Bard Receives FDA 510(k) Approval For Ajust Helical Adjustable Single Incision Sling 189
17.6.2 Feb 17, 2009: C. R. Bard Receives US FDA Approval To Market LifeStent FlexStar Vascular Stent Systems 189
17.6.3 Dec 08, 2008: Bard Receives FDA Approval For The E-Luminexx Vascular Stent 190
17.6.4 Nov 08, 2007: Bard Receives Clearance To Market Agento IC Silver-Coated Endotracheal Tube 190
17.7 Clinical Trials 191
17.7.1 Jul 27, 2012: Bard Announces Enrollment Completion Of Lutonix Drug-Coated Balloon Clinical Trial And Initiation Of Large Continuation Registry Study 191
17.7.2 Jul 25, 2012: Bard Announces Enrollment Completion Of Lutonix Drug-Coated Balloon Clinical Trial And Initiation Of Large Continuation Registry Study 191
17.7.3 Jun 15, 2010: C.R. Bard Announces Publication Of RESILIENT Trial Results Of Bard LIFESTENT Vascular Stent 192
17.7.4 Feb 16, 2010: C.R. Bard To Complete Clinical Trial For Bard Ventrio Hernia Patch In First Half Of 2011 193
17.7.5 Sep 08, 2009: Bard To Complete Phase I Trial For RESTORe Suturing System In Second Half Of 2010 193
17.7.6 Sep 02, 2009: Bard To Complete The Phase III Trial For BARD HD MESH Ablation System In First Half Of 2011 194
17.7.7 Aug 20, 2008: C. R. Bard Inc. Published Clinical Study Results Of Agento I.C. Silver-Coated Endotracheal Tube 194
17.8 Other Significant Developments 195
17.8.1 Nov 28, 2012: Novation Awards Cardiovascular Agreements 195
17.8.2 Aug 15, 2012: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Wound Drainage Products 195
17.8.3 Mar 01, 2012: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Invasive Cardiology Equipment 195
17.8.4 Nov 14, 2011: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Electrophysiology Products 195
18 Appendix 196
18.1 Research Methodology 197
18.2 Secondary Research 197
18.3 Primary Research 197
18.4 Models 198
18.5 Forecasts 198
18.6 Expert Panels 198
18.7 GlobalData Consulting 198
18.8 Currency Conversion 199
18.9 Contact Us 200
18.10 Disclaimer 200
【レポート販売概要】
■ タイトル：C. R. Bard, Inc.：市場シェア分析■ 英文：C. R. Bard, Inc. Market Share Analysis
■ 発行日：2013年2月28日
■ 調査会社：GlobalData
■ 商品コード：GDATA403160482
■ 調査対象地域：グローバル
- 世界の乗用自動車用エアバッグ及びシートベルト市場The major driving the demand of automotive airbag and seatbelt are stringent safety norms, increased safety awareness, technological advancement, affordability as well as institutions such as the New Car Assessment Program (NCAP) awarding safety ratings to cars based on safety performance. In the coming years, the increasing demand for premium cars in the regions such as Europe and Asia Pacific, m …
- 腹水(Ascites)：世界の治験レビュー（2015年上半期版）Ascites Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Ascites Global Clinical Trials Review, H1, 2015" provides data on the Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conductio …
- Adenovirus Diagnostic：医療検査市場2014The report presents a detailed analysis of the Adenovirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Adenovirus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Co …
- ヒドロキシプロピルメチルセルロースフタレートの世界市場HPMCP (CAS 9050-31-1) Market Research Report 2013 presents comprehensive data on praduct markets globally and regionally (Europe, Asia, North America etc.) The HPMCP (CAS 9050-31-1) Market Research Report 2013 includes hpmcp description, covers its application areas and related patterns. It overviews hpmcp market, names hpmcp producers and indicates its suppliers. Besides, the HPMCP (CAS 9050-31-1 …
- 結膜炎治療薬の世界市場：細菌性結膜炎、ウイルス性結膜炎、アレルギー性結膜炎About Conjunctivitis Conjunctivitis, also called pink eye or Madras eye, is an infection in or inflammation of the conjunctiva. It affects either one or both a person's eyes and can be the result of an allergy, bacteria, or a virus. Allergens such as smoke, pollen, dust mites, eye drops, cosmetics, and perfumes can lead to conjunctivitis. It is usually associated with redness of the eye along with …
- グローバルにおける農業用機械・林業用機械市場（～2019）The industry report Global Agricultural and Forestry Machine Market to 2019 - Market Size, Development, and Forecasts offers the most up-to-date market data on the actual market situation, and future outlook for agricultural and forestry machines in the world. The research includes historic market data from 2008 to 2014 and forecasts until 2019 which makes the report an invaluable resource for ind …
- Next Generation Network OSS/BSS Market and Forecast 2010-2015Next Generation Networks (NGN) promises a high quality end-user experience. Telecommunications service providers expect the NGN framework to provide them with tools that would ensure customer loyalty. However, the path towards achieving the ideal NGN is fraught with formidable challenges. The most critical challenge confronting operators is optimizing their OSS and BSS platforms, systems, and proc …
- 世界のマイクロ波装置市場2015The Global Microwave Devices Industry Report 2015 is a professional and in-depth study on the current state of the Microwave Devices industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Microwave Devices market analysis is provided for the international markets including development trends, competitive …
- 小売向けタッチスクリーン・ディスプレイの世界市場About Retail Touch Screen Display A touchscreen display includes a touch sensor, a protection layer, and other components used to detect the touch. A touchscreen is usually operated using fingers or using a stylus depending on the convenience and the type of the touchscreen. It has wide applications; most of them are used in smartphones and tablets. Apart from these, they are used in ATMs, kiosks, …
- Total S.A.社の石油・ガス開発・生産動向及びコスト分析（2013年第4四半期）Total S.A. Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2013 Summary Total S.A. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key operational d …
- 難燃性化学物質の世界市場2016-2020：臭素化難燃性化学物質、塩素化難燃性化学物質、リン系難燃性化学物質、水酸化アルミニウム難燃性化学物質、酸化アンチモン難燃性化学物質About Flame Retardants Chemicals Flame retardant chemicals are added to flammable materials to offer resistance to ignition and for inhibiting or delaying combustion. Bromine, chlorine, phosphorus, aluminum, magnesium, melamine, antimony oxide, and boron are widely used for manufacturing flame retardants. Brominated and chlorinated flame retardants are grouped under halogen-containing flame retard …
- dPCR（デジタルPCR）及びqPCR（定量PCR）の世界市場：PCR装置、PCR用試薬・消耗品、PCRソフトウェア、PCRサービスThe global digital PCR (dPCR) and qPCR market is estimated to grow at a CAGR of 7.8% from 2014 to 2019. Although the mature markets (such as the U.S., Germany, France, and U.K.) hold larger shares in the digital PCR (dPCR) and qPCR market, the Asia-Pacific region is expected to grow at the highest CAGR of ~10.7% in the forecast period. The growth of the digital PCR (dPCR) and qPCR market is driven …
- 風力発電タワーの世界市場2015-2019Technavios market research analyst has estimated that the prospect for growth in this market is strongly driven by the wind energy industry, which is influenced by the rising environmental concerns, increased power demand, favorable government support, and the rising need to reduce dependency on fossil fuels. These factors are expected to stimulate the prospects for growth in this market and resul …
- チモールの世界市場Thymol (CAS 89-83-8) Market Research Report 2013 presents comprehensive data on thymol markets globally and regionally (Europe, Asia, North America etc.) The Thymol (CAS 89-83-8) Market Research Report 2013 includes thymol description, covers its application areas and related patterns. It overviews thymol market, names thymol producers and indicates its suppliers. Besides, the Thymol (CAS 89-83-8) …
- タイヤ物流の世界市場ABSTRACTAbout Tire Logistics Logistics and supply chains for spare parts are unstable when compared with market finished products. Many manufacturing companies are facing setbacks because of an increase in operational costs and a decline in demand from consumers. Vendors of logistics services need to be efficient at services such as data management, IT, and supply chain management. Accurate foreca …
